Nantkwest’s (NK) Hold Rating Reaffirmed at Raymond James Financial
Nantkwest (NASDAQ:NK)‘s stock had its “hold” rating reiterated by analysts at Raymond James Financial in a report issued on Monday.
NK has been the topic of a number of other research reports. Zacks Investment Research raised Nantkwest from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Tuesday, November 14th. Citigroup set a $3.00 price target on Nantkwest and gave the company a “sell” rating in a research report on Monday, August 14th. Finally, BidaskClub lowered Nantkwest from a “sell” rating to a “strong sell” rating in a research report on Friday, September 22nd. Three analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $5.13.
Shares of Nantkwest (NK) traded down $0.01 during trading on Monday, reaching $4.95. The company had a trading volume of 224,900 shares, compared to its average volume of 368,420. Nantkwest has a 12 month low of $2.71 and a 12 month high of $8.45. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.47 and a quick ratio of 5.47.
Several hedge funds and other institutional investors have recently modified their holdings of NK. Renaissance Technologies LLC increased its position in Nantkwest by 1,884.1% during the first quarter. Renaissance Technologies LLC now owns 486,100 shares of the biotechnology company’s stock worth $1,726,000 after buying an additional 461,600 shares during the period. Vanguard Group Inc. increased its position in Nantkwest by 8.4% during the first quarter. Vanguard Group Inc. now owns 2,082,706 shares of the biotechnology company’s stock worth $7,394,000 after buying an additional 160,510 shares during the period. Northern Trust Corp increased its position in Nantkwest by 67.8% during the second quarter. Northern Trust Corp now owns 304,062 shares of the biotechnology company’s stock worth $2,308,000 after buying an additional 122,906 shares during the period. State Street Corp increased its position in Nantkwest by 52.9% during the second quarter. State Street Corp now owns 341,007 shares of the biotechnology company’s stock worth $2,589,000 after buying an additional 117,946 shares during the period. Finally, Alps Advisors Inc. acquired a new position in Nantkwest during the second quarter worth approximately $563,000. 19.14% of the stock is currently owned by institutional investors and hedge funds.
Receive News & Ratings for Nantkwest Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest Inc and related companies with MarketBeat.com's FREE daily email newsletter.